Buket CİNEMRE, Ali Rıza ERDOĞAN, Burak KULAKSIZOĞLU, Özmen METİN, Mehmet Murat KULOĞLU

Comparison of oral naltrexone and naltrexone implant treatment in alcohol use disorders

Objective: The aim of this study is to retrospectively compare the efficacy of long acting naltrexone (XR-NTX) andoral naltrexone (O-NTX) treatment in alcohol use disorder patients. Methods: In the study, retrospective dataincluding sociodemographic characteristics, treatment continuation rates, mean treatment duration (duration ofabstinence) and liver function test results were scanned from the medical records and then analyzed in a group of16 patients and a group of 27 patients who were put on XR-NTX and O-NTX treatments, respectively. Results:87.5% (14 patients) of the XR-NTX treatment group and 88.9% (24 patients) of the O-NTX treatment group comprised of male patients. The mean age in the XR-NTX group was 41.31±10.26 years; whereas it was 42.14±9.07 inthe O-NTX group. Fourteen patients in the XR-NTX (87.5%) and 15 patients (55.6%) in the O-NTX group returnedfor control after the first admission. Thus, treatment compliance was significantly higher in the XR-NTX group thanin the O-NTX group. Conclusion: An increase in treatment compliance with XR-NTX treatment was observed inthe study. This study may suggest that XR-NTX is more efficient than O-NXR in the treatment of alcohol usedisorder. Thus XR-NTX treatment may be a good alternative for patients with alcohol use disorder to stay on treatment for a longer time. (Anatolian Journal of Psychiatry 2020; 21(5):477-482)

Alkol kullanım bozukluğunda oral naltrekson ve naltrekson implant tedavisinin karşılaştırılması

Amaç: Bu çalışmada alkol kullanım bozukluğu hastalarında deri altı implant uzun etkili naltrekson (XR-NTX) ve oral naltrekson (O-NTX) tedavilerinin etkinliğinin karşılaştırılması amaçlanmıştır. Yöntem: Çalışmada, alkol kullanım bozukluğu tedavisi için XR-NTX başlanan 16 hasta ve O-NTX başlanan 27 hastanın sosyodemografik özellikleri, ilk tedavi başlangıcında ve sonrasında, tedaviyi sürdürme oranları, tedavide kalma süreleri (tam abstinens süresi) ve karaciğer fonksiyon test sonuçları geriye dönük olarak hasta dosyaları üzerinden taranmıştır. Bulgular: XR-NTX grubunun %87.5’i (14 hasta), O-NTX grubunun %88.9’u (24 hasta) erkeklerden oluşmaktaydı. XR-NTX grubunda ortalama yaş 41.31±10.26 yıl, O-NTX grubunda 42.14±9.07 yıl idi. XR-NTX grubunda 14 hasta (%87.5), O-NTX grubunda 15 hasta (%55.6) ilk poliklinik muayenesi sonrası tekrar kontrol için başvurmuş olup XR-NTX grubunun tedavi uyumu anlamlı olarak yüksektir. Sonuç: XR-NTX tedavisi ile tedaviye uyumun arttığı saptandı. Bu çalışma ile alkol kullanım bozukluğu tedavisinde XR-NTX tedavisinin O-NTX tedavisinden daha etkili olduğu söylenebilir. Alkol kullanım bozukluğunda hastaların tedaviyi sürdürmesi için XR-NTX tedavisi iyi bir seçenek olabilir. (Anadolu Psikiyatri Derg 2020; 21(5):477-482)

PDF

___

1. World Health Organization. Global Status Report on Alcohol and Health-2014 ed. Geneva, Switzerland: World Health Organization; 2014. Available online at: www.who.int/substance_abuse/ publications/global_alcohol_report/en/ (Accessed on April 14th, 2016)

2. Substance Abuse and Mental Health Services Administration, Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health, HHS Publication No. SMA 17-05==5044, NSDUH Series H-52, 2017 https://www.samhsa. gov/data/ (Accessed date: June 4th, 2018)

3. National Institute of Alcohol Abuse and Alcoholism. Rethinking drinking: alcohol and your health. http://www.rethinkingdrinking.niaaa.nih.go v/isyourdrinkingpatternrisky/whatsatriskoheavydri nking.asp (Accessed December 15th, 2014)

4. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49:881-887. 5. Volpicelli JR, Alterman A, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-880.

6. Volpicelli JR, Davis MA, Olgin JE. Naltrexone blocks the post-shock increase in ethanol consumption. Life Sci 1986; 38(9):841-847. 7. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345:1734-1739.

8. Kranzler HR, Van KJ. Efficacy of naltrexone and acamprosate for alcoholism treatment: a metaanalysis. Alcohol Clin Exp Res 2001; 25:1335- 1341. 9. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36(6):544-552.

10. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54(8):737-742.

11. O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med 2003; 163(14):1695-1704.

12. Naccari C. FDA approves naltrexone for extended-release injectable suspension for the treatment of alcohol dependence. CNS Spectr 2006; 11(5):345-345.

13. Kranzler HR, Wesson DR, Billot L, Drug Abuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004; 28(7):1051-1059.

14. Lee JD, Grossman E, DiRocco D, Truncali A, Hanley K, Stevens D, et al. Extended release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat 2010; 39(1):14- 21.

15. Malone M, McDonald R, Vittitow A, Chen J, Obi R, Schatz D, et al. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Contemp Clin Trials 2019; 81:102-109.

16. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: A combine study: A randomized controlled trial. J Am Med Assoc 2006; 295:2003- 2017.

17. Garbutt JC, Kranzler HR, O'Malley SS., Gastfriend, DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. J Am Med Assoc 2005; 293:1617- 1625.

18. Roozen HG, de Waart R, van den Brink W. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. Eur Addict Res 2007; 13(4):201-206.

19. Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1996; 15(4):274-282.

20. Lee JD, Grossman E, Huben L, Manseau M, McNeely J, Rotrosen J, et al., Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months. J Subst Abuse Treat 2012; 43(4):458-462.

21. Mark TL, Gastfriend DR, Kranzler HR, Chalk M, Montejano L. Characteristics and cost outcomes of insured patients treated with extended-release naltrexone (XR-NTX) or oral alcohol dependence medications. Value Health 2010; 13(3):A106.